1476847-50-3

Basic information

• Product Name: 2-(benzyloxy)-6-hydroxy-4-methoxybenzaldehyde
• Synonyms: 2-(benzyloxy)-6-hydroxy-4-methoxybenzaldehyde;EOS-61408
• CAS NO: 1476847-50-3
• Molecular Formula: C₁₅H₁₄O₄
• Molecular Weight: 258.26926
• Mol File: 1476847-50-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 445.7±40.0 °C(Predicted)
• Appearance: /
• Density: 1.240±0.06 g/cm3(Predicted)
• PKA: 7.42±0.15(Predicted)
• CAS DataBase Reference: 2-(benzyloxy)-6-hydroxy-4-methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzyloxy)-6-hydroxy-4-methoxybenzaldehyde(1476847-50-3)
• EPA Substance Registry System: 2-(benzyloxy)-6-hydroxy-4-methoxybenzaldehyde(1476847-50-3)

Safety Data

• Hazardous Substances Data: 1476847-50-3(Hazardous Substances Data)

Usage

General Description

2-(benzyloxy)-6-hydroxy-4-methoxybenzaldehyde is a chemical compound with a molecular formula of C15H14O4. It is a derivative of benzaldehyde and contains a benzene ring with a benzyloxy group, a hydroxy group, and a methoxy group attached to it in specific positions. The compound has multiple functional groups, making it useful in various applications in organic synthesis and drug synthesis. It is commonly used as an intermediate in the production of pharmaceuticals and natural products due to its unique chemical structure and reactivity. Additionally, 2-(benzyloxy)-6-hydroxy-4-methoxybenzaldehyde has been studied for its potential antioxidant and anticancer properties.

Upstream product

• 83-30-7 acide 2,4,6-trihydroxybenzoique 
• 1132988-93-2 2-hydroxy-4,6-bis(methoxymethoxy)benzaldehyde 
• 67-56-1 methanol 
• 487-70-7 2,4,6-trihydroxybenzaldehyde 
• 1476847-49-0 5-(benzyloxy)-7-methoxy-2,2-dimethyl-4H-benzo[d][1,3 ]dioxin-4-one 
• 100-39-0 benzyl bromide 
• 532394-23-3 5-hydroxy-7-methoxy-2,2-dimethyl-benzo[1,3]dioxin-4-one 
• 137571-73-4 5,7-dihydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 108-73-6 3,5-dihydroxyphenol 

Downstream Products

• 1476847-51-4 1-[4-(benzyloxy)-6-methoxy-1-benzofuran-2-yl]ethan-1-one 
• 1476848-33-5 2-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-6-methylimidazo[1,2-b]pyridazine 
• 1476848-37-9 (S)-6-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-(1-fluoroethyl)imidazo[2,1-b][1,3,4]thiadiazole 
• 1476847-54-7 6-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoimidazo[2,1-b][1,3,4]thiadiazole 
• 1476847-52-5 1-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoethanone 

Relevant articles and documents

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy

In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure-activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.

PAR4 AGONIST PEPTIDES

The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.